Compare · RCKT vs RKT
RCKT vs RKT
Side-by-side comparison of Rocket Pharmaceuticals Inc. (RCKT) and Rocket Companies Inc. (RKT): market cap, price performance, sector, and recent activity on the wire.
Summary
- RCKT operates in Health Care, while RKT operates in Finance - the two are in different parts of the market.
- RKT is the larger of the two at $38.93B, about 98.0x RCKT ($397.5M).
- Over the past year, RCKT is up 24.8% and RKT is down 19.5% - RCKT leads by 44.3 points.
- RKT has been more active in the news (19 items in the past 4 weeks vs 7 for RCKT).
- Both have 25 recent analyst ratings on file.
- Company
- Rocket Pharmaceuticals Inc.
- Rocket Companies Inc.
- Price
- $3.65+1.11%
- $13.77+0.36%
- Market cap
- $397.5M
- $38.93B
- 1M return
- -6.41%
- -4.31%
- 1Y return
- +24.79%
- -19.52%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Finance: Consumer Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- 2020
- News (4w)
- 7
- 19
- Recent ratings
- 25
- 25
Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Rocket Companies Inc.
Rocket Companies, Inc. engages in the tech-driven real estate, mortgage, and eCommerce businesses in the United States and Canada. It operates in two segments, Direct to Consumer and Partner Network. The company's solutions include Rocket Mortgage, a mortgage lender; Amrock that provides title insurance, property valuation, and settlement services; Rocket Homes, a home search platform and real estate agent referral network, which offers technology-enabled services to support the home buying and selling experience; Rocket Auto, an automotive retail marketplace that provides centralized and virtual car sales support to national car rental and online car purchasing platforms; and Rocket Loans, an online-based personal loans business. Its solutions also include Core Digital Media, a digital social and display advertiser in the mortgage, insurance, and education sectors; Nexsys, a fintech company, which offers a suite of essential tech solutions for mortgage origination and closing processes through digitization and automation; Lendesk, a technology services company that provides a point of sale system for mortgage professionals and a loan origination system for private lenders; and Edison Financial, a digital mortgage startup. In addition, the company originates, closes, sells, and services agency-conforming loans. Rocket Companies, Inc. was founded in in 1985 and is headquartered in Detroit, Michigan. Rocket Companies, Inc. is a subsidiary of Rock Holdings, Inc.
Latest RCKT
- Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Rocket Pharmaceuticals Inc.
- Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
- Chief Operating Officer Stevens Christopher James was granted 73,313 shares, increasing direct ownership by 16% to 542,442 units (SEC Form 4)
- Director Southwell David P acquired 150,000 shares, increasing direct ownership by 275% to 204,522 units (SEC Form 4)
- Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
- SEC Form S-8 filed by Rocket Pharmaceuticals Inc.
- New insider Manhede Joseph claimed ownership of 52,576 shares (SEC Form 3)
- Director Dolsten Mikael was granted 22,862 shares, increasing direct ownership by 52% to 67,082 units (SEC Form 4)
Latest RKT
- SEC Form 10-Q filed by Rocket Companies Inc.
- Rocket Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Rocket Companies Announces Second Quarter 2026 Results
- SEC Form SCHEDULE 13G filed by Rocket Companies Inc.
- Redfin Reports Pending Home Sales Sink to 5-Month Low As Mortgage Rates Rise
- Redfin Reports Affordability For U.S. Starter Homes Improves Slightly Faster Than Overall Market
- The Income Needed to Afford Typical American Home Holds Steady Near Record High of $110,000
- Brooklyn's Park Slope is Redfin's Hottest Luxury Neighborhood of 2026
- Redfin Reports Homebuying Demand Slows As Mortgage Rates Hit Highest Level in a Year
- Redfin Reports 15% Fewer Canadians Are Searching for Homes in the U.S. Than Last Year